Comparative Pharmacology
Head-to-head clinical analysis: SANDOSTATIN LAR versus SIGNIFOR LAR KIT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SANDOSTATIN LAR versus SIGNIFOR LAR KIT.
SANDOSTATIN LAR vs SIGNIFOR LAR KIT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Synthetic octapeptide analog of somatostatin with greater metabolic stability and longer duration of action. Inhibits growth hormone (GH) secretion via binding to somatostatin receptors (SSTR2 and SSTR5) on pituitary somatotrophs. Also suppresses insulin-like growth factor-1 (IGF-1), glucagon, and insulin secretion. Reduces splanchnic blood flow and inhibits secretion of gastrointestinal hormones.
Somatostatin analog that binds to somatostatin receptors (primarily sst2 and sst5), inhibiting growth hormone (GH) and insulin-like growth factor 1 (IGF-1) secretion, and reducing hormone release from neuroendocrine tumors.
Octreotide acetate 20 mg intramuscularly every 4 weeks for acromegaly; 20 mg intramuscularly every 4 weeks for neuroendocrine tumors; may initiate at 10 mg for symptom control of carcinoid syndrome and dose titrate based on response.
Intramuscular injection: 40 mg every 28 days.
None Documented
None Documented
Terminal half-life: 12-14 days for subcutaneous octreotide LAR microspheres; clinical steady state achieved after 2-3 injections.
Terminal elimination half-life following intramuscular injection of the long-acting formulation is approximately 19 days (range 15–23 days), supporting monthly dosing intervals.
Renal: 32% as unchanged drug; biliary/fecal: 60-70% via feces as metabolites and unchanged drug.
Primarily renal (approximately 85% of administered dose excreted unchanged in urine); minimal biliary/fecal excretion (less than 10%).
Category C
Category C
Somatostatin Analog
Somatostatin Analog